Endovascular Intervention for Peripheral Artery Disease

Circulation Research

Volumn 116, Issue 9, 2015, Pages 1599-1613

  Thukkani, Arun K ^a   Kinlay, Scott ^b  

^a MISSOURI BAPTIST MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

endovascular procedures; intermittent claudication; peripheral artery disease

Indexed keywords

ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; FIBRINOLYTIC AGENT; PACLITAXEL;

ACUTE LIMB ISCHEMIA; ARTICLE; ATHERECTOMY; ATHERECTOMY DEVICE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CRITICAL LIMB ISCHEMIA; DIRECTIONAL ATHERECTOMY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; EVENT FREE SURVIVAL; FOLLOW UP; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; LIMB SALVAGE; MOTOR DYSFUNCTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RESTENOSIS; REVASCULARIZATION; ROTATIONAL ATHERECTOMY DEVICE; SELF EXPANDING STENT; ISCHEMIA; LEG; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; RISK FACTOR; STENT; VASCULARIZATION;

ANGIOPLASTY, BALLOON; ENDOVASCULAR PROCEDURES; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; LOWER EXTREMITY; PERIPHERAL ARTERIAL DISEASE; QUALITY OF LIFE; RISK FACTORS; STENTS;

EID: 84942846406     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.303503     Document Type: Article

References (131)

1. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): a report of the American College Of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2020-2045.
2. Hirsch AT, Haskal ZJ, Hertzer NR, et al; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463-e654. doi: 10.1161/ CIRCULATIONAHA.106.174526.
3. Wennberg PW. Approach to the patient with peripheral arterial disease. Circulation. 2013;128:2241-2250. doi: 10.1161/ CIRCULATIONAHA.113.000502.
4. Aboyans V, Criqui MH, Abraham P, et al; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126:2890-2909. doi: 10.1161/CIR.0b013e318276fbcb.
5. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, Chan C, Celic L, Pearce WH, Schneider JR, Sharma L, Clark E, Gibson D, Martin GJ. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286:1599-1606.
6. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Rutherford RB; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26:81-157.
7. Berger JS, Hiatt WR. Medical therapy in peripheral artery disease. Circulation. 2012;126:491-500. doi: 10.1161/ CIRCULATIONAHA.111.033886.
8. McDermott MM, Liu K, Guralnik JM, Criqui MH, Spring B, Tian L, Domanchuk K, Ferrucci L, Lloyd-Jones D, Kibbe M, Tao H, Zhao L, Liao Y, Rejeski WJ. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA. 2013;310:57-65. doi: 10.1001/jama.2013.7231.
9. Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med. 2010;15:181-188. doi: 10.1177/1358863X10361545.
10. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481-1486. doi: 10.1161/01. CIR.0000090686.57897.F5.
11. Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, Reid CM, Golledge J, Kingwell BA. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA. 2013;309:453-460. doi: 10.1001/jama.2012.216237.
12. Rieker O, Düber C, Schmiedt W, von Zitzewitz H, Schweden F, Thelen M. Prospective comparison of CT angiography of the legs with intraarterial digital subtraction angiography. AJR Am J Roentgenol. 1996;166:269-276. doi: 10.2214/ajr.166.2.8553929.
13. Schernthaner R, Stadler A, Lomoschitz F, Weber M, Fleischmann D, Lammer J, Loewe Ch. Multidetector CT angiography in the assessment of peripheral arterial occlusive disease: accuracy in detecting the severity, number, and length of stenoses. Eur Radiol. 2008;18:665-671. doi: 10.1007/s00330-007-0822-8.
14. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007;56:3433-3441. doi: 10.1002/ art.22925.
15. Connors G, Todoran TM, Engelson BA, Sobieszczyk PS, Eisenhauer AC, Kinlay S. Percutaneous revascularization of long femoral artery lesions for claudication: patency over 2.5 years and impact of systematic surveillance. Catheter Cardiovasc Interv. 2011;77:1055-1062. doi: 10.1002/ ccd.22802.
16. Bonvini RF, Rastan A, Sixt S, Noory E, Schwarz T, Frank U, Roffi M, Dorsaz PA, Schwarzwälder U, Bürgelin K, Macharzina R, Zeller T. Endovascular treatment of common femoral artery disease: mediumterm outcomes of 360 consecutive procedures. J Am Coll Cardiol. 2011;58:792-798. doi: 10.1016/j.jacc.2011.01.070.
17. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of lowdose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10-19. doi: 10.1016/j.jcin.2013.05.022.
18. Klein AJ, Pinto DS, Gray BH, Jaff MR, White CJ, Drachman DE. SCAI expert consensus statement for femoral-popliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84:529-538. doi: 10.1002/ccd.25504.
19. Klein AJ, Feldman DN, Aronow HD, Gray BH, Gupta K, Gigliotti OS, Jaff MR, Bersin RM, White CJ. SCAI expert consensus statement for aorto- iliac arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84:520-528. doi: 10.1002/ccd.25505.
20. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation. 1970;41:875-883.
21. Muluk SC, Muluk VS, Kelley ME, Whittle JC, Tierney JA, Webster MW, Makaroun MS. Outcome events in patients with claudication: A 15-year study in 2777 patients. J Vasc Surg. 2001;33:251-257; discussion 257-258
22. Aquino R, Johnnides C, Makaroun M, Whittle JC, Muluk VS, Kelley ME, Muluk SC. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. J Vasc Surg. 2001;34:962-970. doi: 10.1067/ mva.2001.119749.
23. Zeller T. Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med. 2007;12:223-234. doi: 10.1177/1358863X07079823.
24. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997;204:87-96. doi: 10.1148/radiology.204.1.9205227.
25. Tetteroo E, van der Graaf Y, Bosch JL, van Engelen AD, Hunink MG, Eikelboom BC, Mali WP. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet. 1998;351:1153-1159.
26. Klein WM, van der Graaf Y, Seegers J, Spithoven JH, Buskens E, van Baal JG, Buth J, Moll FL, Overtoom TT, van Sambeek MR, Mali WP. Dutch iliac stent trial: long-term results in patients randomized for primary or selective stent placement. Radiology. 2006;238:734-744. doi: 10.1148/ radiol.2382041053.
27. AbuRahma AF, Hayes JD, Flaherty SK, Peery W. Primary iliac stenting versus transluminal angioplasty with selective stenting. J Vasc Surg. 2007;46:965-970. doi: 10.1016/j.jvs.2007.07.027.
28. Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2011;4:1011-1019. doi: 10.1016/j.jcin.2011.06.012.
29. Goode SD, Cleveland TJ, Gaines PA; STAG Trial Collaborators. Randomized clinical trial of stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial). Br J Surg. 2013;100:1148-1153. doi: 10.1002/bjs.9197.
30. Ponec D, Jaff MR, Swischuk J, Feiring A, Laird J, Mehra M, Popma JJ, Donohoe D, Firth B, Keim E, Snead D; CRISP Study Investigators. The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. J Vasc Interv Radiol. 2004;15:911-918. doi: 10.1097/01.RVI.0000140935.45313.35.
31. Wiesinger B, Beregi JP, Oliva VL, Dietrich T, Tepe G, Bosiers M, Hüttl K, Müller-Hülsbeck S, Bray A, Tielemans H, Duda SH. PTFE-covered selfexpanding nitinol stents for the treatment of severe iliac and femoral artery stenoses and occlusions: final results from a prospective study. J Endovasc Ther. 2005;12:240-246. doi: 10.1583/04-1327MR.1.
32. Lammer J, Dake MD, Bleyn J, Katzen BT, Cejna M, Piquet P, Becker GJ, Settlage RA. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. Radiology. 2000;217:95-104. doi: 10.1148/ radiology.217.1.r00se0595.
33. Fischer M, Schwabe C, Schulte KL. Value of the hemobahn/viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. J Endovasc Ther. 2006;13:281-290. doi: 10.1583/05-1799.1.
34. Mwipatayi BP, Thomas S, Wong J, Temple SE, Vijayan V, Jackson M, Burrows SA; Covered Versus Balloon Expandable Stent Trial (COBEST) Co-Investigators. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011;54:1561-1570. doi: 10.1016/j.jvs.2011.06.097.
35. Bekken JA, Vos JA, Aarts RA, de Vries JP, Fioole B. DISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloonexpandable stents in the common iliac artery: study protocol for a randomized controlled trial. Trials. 2012;13:215. doi: 10.1186/1745-6215-13-215.
36. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888. doi: 10.1056/NEJMoa051303.
37. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tübler T, Zeller T. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285-292. doi: 10.1161/CIRCULATIONAHA.107.689141.
38. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Cao AY, Jaff MR; RESILIENT Investigators. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1-9. doi: 10.1583/11-3627.1.
39. Zdanowski Z, Albrechtsson U, Lundin A, Jonung T, Ribbe E, Thörne J, Norgren L. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol. 1999;18:251-255.
40. Becquemin JP, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg. 2003;37:487-494. doi: 10.1067/mva.2003.155.
41. Grimm J, Müller-Hülsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12:935-942.
42. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol. 1997;20:420-425.
43. Schlager O, Dick P, Sabeti S, Amighi J, Mlekusch W, Minar E, Schillinger M. Long-segment SFA stenting-the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;12:676-684. doi: 10.1583/05-1672.1.
44. Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräunlich S, Ulrich M, Biamino G, Schmidt A. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-315. doi: 10.1016/j.jacc.2004.11.026.
45. Laird JR, Jain A, Zeller T, Feldman R, Scheinert D, Popma JJ, Armstrong EJ, Jaff MR; Complete SE Investigators. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelvemonth results from the complete SE multicenter trial. J Endovasc Ther. 2014;21:202-212. doi: 10.1583/13-4548R.1.
46. George JC, Rosen ES, Nachtigall J, VanHise A, Kovach R. SUPERA interwoven nitinol Stent Outcomes in Above-Knee IntErventions (SAKE) study. J Vasc Interv Radiol. 2014;25:954-961. doi: 10.1016/j. jvir.2014.03.004.
47. Scheinert D, Werner M, Scheinert S, Paetzold A, Banning-Eichenseer U, Piorkowski M, Ulrich M, Bausback Y, Bräunlich S, Schmidt A. Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv. 2013;6:65-71. doi: 10.1016/j.jcin.2012.09.011.
48. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi JP. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106:1505-1509.
49. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Mudde C, Tielemans H, Bérégi JP. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-338. doi: 10.1097/01.RVI.0000151260.74519.CA.
50. Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394-401. doi: 10.1016/j.jvs.2011.01.047.
51. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Snyder SA, O'Leary EE, Tepe G, Scheinert D, Zeller T; Zilver PTX Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417-2427. doi: 10.1016/j.jacc.2013.03.034.
52. De Cock E, Sapoval M, Julia P, de Lissovoy G, Lopes S. A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France. Cardiovasc Intervent Radiol. 2013;36:362-370. doi: 10.1007/ s00270-012-0494-x.
53. Saxon RR, Dake MD, Volgelzang RL, Katzen BT, Becker GJ. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008;19:823-832. doi: 10.1016/j.jvir.2008.02.008.
54. Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM; VIBRANT Investigators. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58:386-95.e4. doi: 10.1016/j.jvs.2013.01.050.
55. Saxon RR, Chervu A, Jones PA, Bajwa TK, Gable DR, Soukas PA, Begg RJ, Adams JG, Ansel GM, Schneider DB, Eichler CM, Rush MJ. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013;24:165-73; quiz 174. doi: 10.1016/j.jvir.2012.10.004.
56. Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, Rand T, Funovics M, Wolf F, Rastan A, Gschwandtner M, Puchner S, Ristl R, Schoder M. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62:1320-1327. doi: 10.1016/j.jacc.2013.05.079.
57. Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M, Hamm B. Neointima inhibition: comparison of effectiveness of nonstent- based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006;240:411-418. doi: 10.1148/radiol.2402051248.
58. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699. doi: 10.1056/NEJMoa0706356.
59. Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U, Eschenbach G, Hartmann H, Lange C, Schnorr B, Stiepani H, Zoccai GB, Hänninen EL. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831-840. doi: 10.1161/ CIRCINTERVENTIONS.112.971630.
60. Fanelli F, Cannavale A, Corona M, Lucatelli P, Wlderk A, Salvatori FM. The "DEBELLUM"-lower limb multilevel treatment with drug eluting balloon-randomized trial: 1-year results. J Cardiovasc Surg (Torino). 2014;55:207-216.
61. Liistro F, Grotti S, Porto I, Angioli P, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G, Bolognese L. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATESFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295-1302. doi: 10.1016/j.jcin.2013.07.010.
62. Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, Grattoni C, Pantaleo P, Cremonesi A, Rubino P, Biamino G. 2-year results of paclitaxel- eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. JACC Cardiovasc Interv. 2013;6:282-289. doi: 10.1016/j.jcin.2013.01.128.
63. Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, Tesorio T, Cota L, Popusoi G, Pucciarelli A, Esposito G, Trimarco B, Rubino P. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014;7:411-415. doi: 10.1016/j.jcin.2013.11.020.
64. Bosiers M, Hart JP, Deloose K, Verbist J, Peeters P. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. Vascular. 2006;14:63-69.
65. Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: A 10-year experience. J Vasc Surg. 2005;41:423-435; discussion 435
66. Krankenberg H, Sorge I, Zeller T, Tübler T. Percutaneous transluminal angioplasty of infrapopliteal arteries in patients with intermittent claudication: acute and one-year results. Catheter Cardiovasc Interv. 2005;64:12-17. doi: 10.1002/ccd.20237.
67. Rastan A, Brechtel K, Krankenberg H, Zahorsky R, Tepe G, Noory E, Schwarzwälder U, Macharzina R, Schwarz T, Bürgelin K, Sixt S, Tübler T, Neumann FJ, Zeller T. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: longterm results from a randomized trial. J Am Coll Cardiol. 2012;60:587-591. doi: 10.1016/j.jacc.2012.04.035.
68. Wolfe JH, Wyatt MG. Critical and subcritical ischaemia. Eur J Vasc Endovasc Surg. 1997;13:578-582.
69. Lepäntalo M, Mätzke S. Outcome of unreconstructed chronic critical leg ischaemia. Eur J Vasc Endovasc Surg. 1996;11:153-157.
70. Bertelè V, Roncaglioni MC, Pangrazzi J, Terzian E, Tognoni EG. Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur J Vasc Endovasc Surg. 1999;18:401-410. doi: 10.1053/ejvs.1999.0934.
71. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H; BASIL Trial Participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925-1934. doi: 10.1016/S0140-6736(05)67704-5.
72. Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975-981. doi: 10.1016/j. jvs.2008.01.005.
73. DeRubertis BG, Pierce M, Ryer EJ, Trocciola S, Kent KC, Faries PL. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg. 2008;47:101-108. doi: 10.1016/j.jvs.2007.09.018.
74. Rueda CA, Nehler MR, Perry DJ, McLafferty RB, Casserly IP, Hiatt WR, Peyton BD. Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: Implications for clinical trial design. J Vasc Surg. 2008;47:995-999; discussion 999-1000
75. Kawarada O, Fujihara M, Higashimori A, Yokoi Y, Honda Y, Fitzgerald PJ. Predictors of adverse clinical outcomes after successful infrapopliteal intervention. Catheter Cardiovasc Interv. 2012;80:861-871. doi: 10.1002/ ccd.24370.
76. Biancari F, Juvonen T. Angiosome-targeted lower limb revascularization for ischemic foot wounds: systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2014;47:517-522. doi: 10.1016/j.ejvs.2013.12.010.
77. Nishibe T, Kondo Y, Dardik A, Muto A, Koizumi J, Nishibe M. Hybrid surgical and endovascular therapy in multifocal peripheral TASC D lesions: up to three-year follow-up. J Cardiovasc Surg (Torino). 2009;50:493-499.
78. Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol. 2001;12:923-933.
79. Kandarpa K, Becker GJ, Hunink MG, McNamara TO, Rundback JH, Trost DW, Sos TA, Poplausky MR, Semba CP, Landow WJ. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol. 2001;12:683-695.
80. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221:137-145. doi: 10.1148/radiol.2211010039.
81. Hu H, Zhang H, He Y, Jin W, Tian L, Chen X, Li M. Endovascular nitinol stenting for long occlusive disease of the superficial femoral artery in critical limb ischemia: a single-center, mid-term result. Ann Vasc Surg. 2011;25:210-216. doi: 10.1016/j.avsg.2010.09.013.
82. Lichtenberg M, Stahlhoff W, Boese D. Superficial femoral artery TASC D Registry: twelve-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013;54:433-439.
83. Todoran TM, Connors G, Engelson BA, Sobieszczyk PS, Eisenhauer AC, Kinlay S. Femoral artery percutaneous revascularization for patients with critical limb ischemia: outcomes compared to patients with claudication over 2.5 years. Vasc Med. 2012;17:138-144. doi: 10.1177/1358863X12440141.
84. Fernandez N, McEnaney R, Marone LK, Rhee RY, Leers S, Makaroun M, Chaer RA. Multilevel versus isolated endovascular tibial interventions for critical limb ischemia. J Vasc Surg. 2011;54:722-729. doi: 10.1016/j. jvs.2011.03.232.
85. Fernandez N, McEnaney R, Marone LK, Rhee RY, Leers S, Makaroun M, Chaer RA. Predictors of failure and success of tibial interventions for critical limb ischemia. J Vasc Surg. 2010;52:834-842. doi: 10.1016/j. jvs.2010.04.070.
86. Söderström MI, Arvela EM, Korhonen M, Halmesmäki KH, Albäck AN, Biancari F, Lepäntalo MJ, Venermo MA. Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: a propensity score analysis. Ann Surg. 2010;252:765-773. doi: 10.1097/SLA.0b013e3181fc3c73.
87. Schmidt A, Ulrich M, Winkler B, Klaeffling C, Bausback Y, Bräunlich S, Botsios S, Kruse HJ, Varcoe RL, Kum S, Scheinert D. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2010;76:1047-1054. doi: 10.1002/ccd.22658.
88. Schmidt A, Piorkowski M, Werner M, Ulrich M, Bausback Y, Bräunlich S, Ick H, Schuster J, Botsios S, Kruse HJ, Varcoe RL, Scheinert D. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105-1109. doi: 10.1016/j.jacc.2011.05.034.
89. Liistro F, Porto I, Angioli P, Grotti S, Ricci L, Ducci K, Falsini G, Ventoruzzo G, Turini F, Bellandi G, Bolognese L. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615-621. doi: 10.1161/ CIRCULATIONAHA.113.001811.
90. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, Peeters P, Vermassen F, Landini M, Snead DB, Kent KC, Rocha-Singh KJ; IN.PACT DEEP Trial Investigators. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568-1576. doi: 10.1016/j.jacc.2014.06.1198.
91. Laird JR, Armstrong EJ. Drug-coated balloons for infrapopliteal disease: digging deep to understand the impact of a negative trial. J Am Coll Cardiol. 2014;64:1577-1579. doi: 10.1016/j.jacc.2014.07.960.
92. Sarode K, Spelber DA, Bhatt DL, Mohammad A, Prasad A, Brilakis ES, Banerjee S. Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. JACC Cardiovasc Interv. 2014;7:827-839. doi: 10.1016/j.jcin.2014.05.008.
93. Scheinert D, Ulrich M, Scheinert S, Sax J, Bräunlich S, Biamino G. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. EuroIntervention. 2006;2:169-174.
94. Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Kraniotis P, Diamantopoulos A, Tsolakis J. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther. 2007;14:241-250. doi: 10.1583/1545-1550(2007)14[241:SVBSAS]2 .0.CO;2.
95. Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, Schmidt A, Tessarek J, Vinck E, Schwartz LB. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55:390-398. doi: 10.1016/j.jvs.2011.07.099.
96. Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M, Krankenberg H, Baumgartner I, Siablis D, Lammer J, Van Ransbeeck M, Qureshi AC, Stoll HP; ACHILLES Investigators. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60:2290-2295. doi: 10.1016/j.jacc.2012.08.989.
97. Rand T, Lammer J, Rabbia C, Maynar M, Zander T, Jahnke T, Müller- Hülsbeck S, Scheinert D, Manninen HI. Percutaneous transluminal angioplasty versus turbostatic carbon-coated stents in infrapopliteal arteries: InPeria II trial. Radiology. 2011;261:634-642. doi: 10.1148/ radiol.11101357.
98. Randon C, Jacobs B, De Ryck F, Vermassen F. Angioplasty or primary stenting for infrapopliteal lesions: results of a prospective randomized trial. Cardiovasc Intervent Radiol. 2010;33:260-269. doi: 10.1007/ s00270-009-9765-6.
99. Eliason JL, Wainess RM, Proctor MC, Dimick JB, Cowan JA Jr, Upchurch GR Jr, Stanley JC, Henke PK. A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann Surg. 2003;238:382-389; discussion 389. doi: 10.1097/01. sla.0000086663.49670.d1.
100. Earnshaw JJ, Whitman B, Foy C. National Audit of Thrombolysis for Acute Leg Ischemia (NATALI): clinical factors associated with early outcome. J Vasc Surg. 2004;39:1018-1025. doi: 10.1016/j.jvs.2004.01.019.
101. Ouriel K, Shortell CK, DeWeese JA, Green RM, Francis CW, Azodo MV, Gutierrez OH, Manzione JV, Cox C, Marder VJ. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg. 1994;19:1021-1030.
102. Weaver FA, Comerota AJ, Youngblood M, Froehlich J, Hosking JD, Papanicolaou G. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity. J Vasc Surg. 1996;24:513-521; discussion 521.
103. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med. 1998;338:1105-1111. doi: 10.1056/ NEJM199804163381603.
104. Berridge DC, Kessel DO, Robertson I. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev. 2013;6:CD002784. doi: 10.1002/14651858.CD002784.pub2.
105. Morgenstern BR, Getrajdman GI, Laffey KJ, Bixon R, Martin EC. Total occlusions of the femoropopliteal artery: high technical success rate of conventional balloon angioplasty. Radiology. 1989;172:937-940. doi: 10.1148/172.3.937.
106. van der Heijden FH, Eikelboom BC, Banga JD, Mali WP. Management of superficial femoral artery occlusive disease. Br J Surg. 1993;80:959-963.
107. Ingle H, Nasim A, Bolia A, Fishwick G, Naylor R, Bell PR, Thompson MM. Subintimal angioplasty of isolated infragenicular vessels in lower limb ischemia: long-term results. J Endovasc Ther. 2002;9:411-416. doi: 10.1583/1545-1550(2002)009<0411:SAOIIV>2.0.CO;2.
108. Gandini R, Volpi T, Pipitone V, Simonetti G. Intraluminal recanalization of long infrainguinal chronic total occlusions using the Crosser system. J Endovasc Ther. 2009;16:23-27. doi: 10.1583/08-2520.1.
109. Al-Ameri H, Mayeda GS, Shavelle DM. Use of high-frequency vibrational energy in the treatment of peripheral chronic total occlusions. Catheter Cardiovasc Interv. 2009;74:1110-1115. doi: 10.1002/ccd.22163.
110. Laird JR, Zeller T, Gray BH, Scheinert D, Vranic M, Reiser C, Biamino G; LACI Investigators. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther. 2006;13:1-11. doi: 10.1583/05-1674.1.
111. Pigott JP, Raja ML, Davis T; Connect Trial Investigators. A multicenter experience evaluating chronic total occlusion crossing with the Wildcat catheter (the CONNECT study). J Vasc Surg. 2012;56:1615-1621. doi: 10.1016/j.jvs.2012.06.071.
112. Schwindt A, Reimers B, Scheinert D, Selmon M, Pigott JP, George JC, Robertson G, Janzer S, McDaniel HB, Shrikhande GV, Torsello G, Schaefers J, Saccà S, Versaci F. Crossing chronic total occlusions with the Ocelot system: the initial European experience. EuroIntervention. 2013;9:854-862. doi: 10.4244/EIJV9I7A139.
113. Wang JB, Zhao JG, Li MH, Zhu YQ, Wang J, Zhang PL. An effective guidewire looping technique for the recanalization of occlusive segments of infrapopliteal vessels. Korean J Radiol. 2010;11:441-448. doi: 10.3348/kjr.2010.11.4.441.
114. Soga Y, Iida O, Suzuki K, Hirano K, Kawasaki D, Shintani Y, Suematsu N, Yamaoka T. Initial and 3-year results after subintimal versus intraluminal approach for long femoropopliteal occlusion treated with a self-expandable nitinol stent. J Vasc Surg. 2013;58:1547-1555. doi: 10.1016/j. jvs.2013.05.107.
115. McKinsey JF, Zeller T, Rocha-Singh KJ, Jaff MR, Garcia LA; DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7:923-933. doi: 10.1016/j.jcin.2014.05.006.
116. Lee MS, Yang T, Adams G. Pooled analysis of the CONFIRM registries: safety outcomes in diabetic patients treated with orbital atherectomy for peripheral artery disease. J Endovasc Ther. 2014;21:258-265. doi: 10.1583/13-4449MR.1.
117. Ambler GK, Radwan R, Hayes PD, Twine CP. Atherectomy for peripheral arterial disease. Cochrane Database Syst Rev. 2014;3:CD006680. doi: 10.1002/14651858.CD006680.pub2.
118. Shammas NW, Dippel EJ, Coiner D, Shammas GA, Jerin M, Kumar A. Preventing lower extremity distal embolization using embolic filter protection: results of the PROTECT registry. J Endovasc Ther. 2008;15:270-276. doi: 10.1583/08-2397.1.
119. Saha SP, Whayne TF Jr, Mukherjee D. Current evidence for antithrombotic therapy after peripheral vascular interventions. Curr Vasc Pharmacol. 2013;11:507-513.
120. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, Loewe C, Cejna M, Lammer J, Minar E. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745-2749. doi: 10.1161/ CIRCULATIONAHA.107.688341.
121. Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. Eur J Vasc Endovasc Surg. 2012;44:577-581. doi: 10.1016/j.ejvs.2012.09.020.
122. Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012;79:541-548. doi: 10.1002/ccd.23304.
123. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 2008;48:144-149. doi: 10.1016/j. jvs.2008.02.062.
124. Dick F, Ricco JB, Davies AH, et al. Chapter VI: Follow-up after revascularisation. Eur J Vasc Endovasc Surg. 2011;42 Suppl 2:S75-S90. doi: 10.1016/S1078-5884(11)60013-0.
125. Hawdon AJ, Davies AH. Vein graft surveillance: is the yield worth the effort? Acta Chir Belg. 2003;103:379-382.
126. Sobieszczyk P, Eisenhauer A. Management of patients after endovascular interventions for peripheral artery disease. Circulation. 2013;128:749-757. doi: 10.1161/CIRCULATIONAHA.113.001560.
127. Kinlay S. Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease. Circulation. 2013;127:1241-1250. doi: 10.1161/ CIRCULATIONAHA.112.001232.
128. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517-538.
129. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-67. doi: 10.1016/j.jvs.2006.12.037.
130. Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta. 1954;21:499-533.
131. Creager MA, Kaufman JA, Conte MS. Clinical practice. Acute limb ischemia. N Engl J Med. 2012;366:2198-2206. doi: 10.1056/ NEJMcp1006054.